Chul Kim

Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2-positive breast cancer.

G. Lyman, G. Curigliano, X. Pivot, 2019, European journal of cancer.

The Effect of ZD 1839 (Iressa(R)) in the Treatment of Refractory Non Small Cell Lung Cancer.

S. Park, Soo Young Park, S. K. Kim, 2003, Cancer research and treatment : official journal of Korean Cancer Association.

Overexpression of Endoplasmic Reticulum Oxidoreductin 1-α (ERO1L) Is Associated with Poor Prognosis of Gastric Cancer

S. Choi, S. Hong, S. Yoon, 2016, Cancer research and treatment : official journal of Korean Cancer Association.

Infusional 5-Fluorouracil, Leucovorin and Docetaxel in Advanced Gastric Cancer.

J. Roh, So Hun Kim, H. Chung, 2003, Cancer research and treatment : official journal of Korean Cancer Association.

A case of paraneoplastic nephrotic syndrome in a patient with ovarian carcinoma.

J. Roh, H. Chung, S. Rha, 2003, Yonsei medical journal.

A P hase II Study of G em citabine M onotherapy in B reast C ancer Patients R efractory to A nthracycline and T axane

G. Kim, H. Chung, J. Sohn, 2002 .

Phase II Study of Topotecan and Etoposide as Second-line Treatment in Chemotherapy-refractory Small-cell Lung Cancer.

S. K. Kim, Joon Chang, J. Sohn, 2002, Cancer research and treatment : official journal of Korean Cancer Association.

Four-year follow-up of a phase III study comparing SB3 (trastuzumab biosimilar) and reference trastuzumab in HER2-positive early or locally advanced breast cancer in neoadjuvant setting.

H. Rugo, G. Lyman, G. Curigliano, 2020 .

A Phase II Study of Gemcitabine Monotherapy in Breast Cancer Patients Refractory to Anthracycline and Taxane.

G. Kim, H. Chung, S. Rha, 2002, Cancer research and treatment : official journal of Korean Cancer Association.